PDF

POSITION STATEMENT

Meningococcal vaccines in Canada: An update

Posted: Oct 1 2011

The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.

Principal author(s)

MI Salvadori, R Bortolussi; Canadian Paediatric Society, Infectious Diseases and Immunization Committee
Abridged version: Paediatr Child Health 2011;16(8):485-6

Abstract

Meningococcal infection is serious, often resulting in fulminant sepsis or meningitis. There are two main types of meningococcal conjugate vaccine currently available in Canada: serotype C meningococcal conjugate, and quadrivalent conjugate for serotypes A, C, Y, and W-135. The immunological characteristics that inform ongoing immunization policies, as well as some of the limits of current knowledge, are presented. All Canadian children should receive a conjugate meningococcal C vaccine (MCV-C) at 12 months of age, and either a booster dose of MCV-C or of quadrivalent meningococcal vaccine (MCV-4) in adolescence. Children at high risk of invasive meningococcal disease should start MCV-C at 2 months of age, and be given MCV-4 at two years of age.

Key Words: Adolescents, Children, Canada; MCV-4; Meningococcal infection; Meningococcal vaccine

In 2002, the Canadian Paediatric Society issued a statement on meningococcal vaccine for children [1] that made recommendations for the use of meningococcal serogroup C conjugate vaccine (MCV-C). As of December 2010, all provinces and territories have implemented publicly-funded, universal immunization programs in a wide range of age groups; some have also implemented catch-up programs [1]. In 2009, the Canadian Paediatric Society issued a statement covering the use of a quadrivalent meningococcal conjugate vaccine for serogroups A, C, Y, and W-135 (MCV-4), providing recommendations on when it may be useful [2](Table 1). Since then, several provinces and territories have implemented publicly-funded programs [3]-[5]. The present statement replaces all previous statements on meningococcal vaccines and updates the present epidemiology of disease caused by this organism in Canada.

TABLE 1
Meningococcal vaccines in Canada

Vaccine

Brand name

Suggested uses

MCV-4
Quadrivalent meningococcal conjugate (A, C, Y, W-135)

Menactra
Menveo

  • Adolescent booster
  • After age two in groups at increased risk

MCV-C
Meningococcal serogroup C conjugate vaccine

Meningitec
Menjugate
Neis Vac-C

  • One dose in second year of life (12 months)
  • For infants at increased risk, a dose at two, four and 12 months of age
  • Adolescent booster

Polysaccharide A, C, Y, W-135

Menomune

No longer useful in paediatrics

Clinical presentations and epidemiology

Neisseria meningitidis is a Gram-negative diplococcus that is usually associated with asymptomatic nasopharyngeal carriage. Sometimes, however, this organism causes septicemia, meningitis, septic arthritis, pneumonia and conjunctivitis. The severity of cases ranges from occult bacteremia to a fulminant and fatal disease. Mortality rates average 10% for invasive disease, with higher rates for septicemic disease (ie, meningococcemia) and serogroup C infection. The incidence of invasive disease varies widely throughout the world. In Canada, the rate of one per 100,000 people is in the intermediate range. Although the disease burden from invasive meningococcal disease in Canada is lower than for other invasive bacterial infections (eg, pneumococcal disease), cases of meningococcal infection generate great fear and anxiety in both physicians and parents. Media interest in this disease is unwavering.

Five serogroups (A, B, C, Y, and W-135, based on the polysaccharide capsule) cause virtually all meningococcal infections in Canada, with serogroups B and C predominating. Although the incidence of serogroup Y disease has increased in the United States among adolescents and adults, a similar increase has not occurred in Canada. Serogroup B disease occurs endemically in Canada, with a peak incidence in children younger than five years of age. Over 70% of cases in this age group are now due to serogroup B. Serogroup C disease often occurs in outbreaks, with a peak in adolescents from 15 to 19 years of age. Serogroup C disease is associated with a higher rate of septicemic disease and higher mortality than with other serogroups, particularly among adolescents. Since the introduction of publicly-funded MCV-C immunization programs for infants, there has been a substantial decrease in meningococcal serogroup C incidence, with no evidence of its replacement with other meningococcal serotypes [6]-[8].

Vaccine development

Before 2001, meningococcal vaccines available in Canada consisted of purified capsular polysaccharide against one or more serogroups. The most commonly used vaccine was the quadrivalent A, C, Y, W-135 vaccine. Although immunogenic and effective in older children and adults, the vaccine was poorly immunogenic in young infants and did not provide long-term protection at any age. First, conjugate meningococcal C vaccines became available, then the quadrivalent conjugated vaccine (MCV-4, Menactra) was licensed in Canada in 2007. A second MCV-4 vaccine (Menveo) was licensed in Canada in 2010. MCV-4 induces protective antibodies to serogroups A, C, Y, and W-135 in adults and in children two years of age or older. Studies on MCV-4 (Menveo) in infants are underway. It is unclear whether MCV-4 will protect children under 2 years of age against serogroup C, or against other serogroups in this age group, as effectively as MCV-C. Serious adverse events from MCV-4 are rare [2].

Meningococcal serogroup B organisms are now the most common cause of meningococcal infection in Canada. The challenge in developing a vaccine is that the polysaccharide of serogroup B is poorly immunogenic in humans. However, vaccines targeting non-polysaccharide surface antigens are under development and show considerable promise. Such a vaccine will be a major breakthrough, because serogroup B strains now cause the majority of invasive meningococcal infections in Canada.

Conjugate meningococcal vaccines induce strong antibody responses and prime the immune system for good memory responses. Universal vaccination programs may also reduce disease by conferring herd immunity. However, unlike many other infectious diseases, meningococcal disease has a very short incubation period (even as short as 48 hrs). It is thought that the anamnestic response cannot be relied upon to prevent disease and that circulating antibodies are needed at all times for protection. Thus, many experts believe lifetime protection cannot be achieved with a primary vaccination, and boosters will be needed. Many provinces and the three territories now have booster programs with MCV-C or MCV-4 for school-aged children. How often boosters will be required is, as yet, unknown.

Every province and territory offers publicly-funded, universal MCV-C vaccination programs for young children [4][5]. All offer a dose at 12 months of age, with two provinces and two territories also providing doses at 2±4 months of age. Although immunization of infants less than 12 months of age may prevent a small number of additional cases, it requires considerable cost per case prevented [9]. In addition, immunizing an infant less than 12 months of age fails to confer protection once the infant is over a year old. Thus, it is critical that at least one dose in a MCV-C vaccine program be given at or after 12 months of age for all infants.

Since serogroup trends differ between Canada and the United States, it will be critical to continue Canadian surveillance programs [8]. The Canadian Immunization Monitoring Program ACTive (IMPACT) monitors all vaccine-preventable infections in Canada. Health care professionals who administer vaccines should assist in this process by reporting possible adverse events and vaccine failures. Strategies to protect the Canadian population against meningococcal infection will continue to evolve as serogroups shift, as newer and better vaccines become available, and as more becomes known about persistence of protective antibodies after immunization.

Recommendations

In view of the safety, immunogenicity and effectiveness of meningococcal vaccines, as well as the severity of some Neisseria meningitidis infections and public concern about the risk of severe meningococcal disease, the Canadian Paediatric Society recommends the following:

  • Canadian children should be immunized with a MCV-C at 12 months of age. Other infants may begin MCV-C immunizations at an earlier age, depending on provincial or territorial vaccine programs and the most up-to-date recommendations published by the National Advisory Committee on Immunization [3][7][8].
  • Infants at increased risk for invasive meningococcal infection (Table 2) should begin MCV-C immunization at two months of age.
  • MCV-4 should be given to children two years of age and older who are at increased risk for meningococcal infection (Table 2). MCV-4 may also be considered for HIV-positive children two years of age or older.
  • All adolescents should be offered a booster dose with MCV-4 or MCV-C at approximately 12 years of age. How often boosters will be required later in life is unknown. Both vaccines are generally safe and well tolerated.

To report possible adverse events associated with vaccines, go to www.phac-aspc.gc.ca/im/aefi-form-eng.php.

TABLE 2
Groups at increased risk of invasive meningococcal disease

Persons with anatomical or functional asplenia (eg, patients with sickle cell anemia)

Children with primary antibody deficiency disorders

Persons who have complement, properdin or factor D deficiency

Travellers to areas where meningococcal risk is high

Laboratory personnel with exposure to meningococcus

The military

Acknowledgements

 This position statement has been reviewed by the Canadian Paediatric Society’s Community Paediatrics Committee. 

INFECTIOUS DISEASES AND IMMUNIZATION COMMITTEE

Members: Jane C Finlay MD; Susanna Martin MD (Board Representative); Jane C McDonald MD; Heather Onyett MD; Joan L Robinson MD (Chair)
Liaisons: Upton D Allen MD, Canadian Pediatrics AIDS Research Group; Janet Dollin MD, The College of Family Physicians of Canada; Charles PS Hui MD, Health Canada, Committee to Advise on Tropical Medicine and Travel); Nicole Le Saux MD, Canadian Immunization Monitoring Program ACTive); Larry Pickering MD, American Academy of Pediatrics, Committee on Infectious Diseases; Marina I Salvadori MD, National Advisory Committee on Immunization; John S Spika MD, Public Health Agency of Canada
Consultants: Robert Bortolussi MD; Noni E MacDonald MD; Dorothy L Moore MD
Principal authors: Marina I Salvadori MD; Robert Bortolussi MD

References

  1. Embree J; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Meningococcal vaccine for children. Paediatr Child Health 2002;7(6):425-6.
  2. Bortolussi R, Salvadori M; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. A new meningococcal conjugate vaccine: What should physicians know and do? Paediatr Child Health 2009;14(8):515-20.
  3. MacDonald NE, Bortolussi R; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. A harmonized immunization schedule for Canada: A call to action. Paediatr Child Health 2011;16(1):29-31.
  4. Public Health Agency of Canada, National Advisory Committee on Immunization (NACI). Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. CCDR 2009;35(ACS-3):2-36. http://origin.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/acs-dcc-3/index-eng.php (Accessed on August 4, 2011).
  5. Public Health Agency of Canada. Publicly funded immunization programs in Canada – Routine schedule for infants and children including special programs and catch-up programs (as of March 2011). http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1_e.html (Accessed on August 4, 2011).
  6. Public Health Agency of Canada. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. CCDR 2007;33:1-15. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07vol33/dr3310a-eng.php (Accessed on August 4, 2011).
  7. Canadian Immunization Monitoring Program, Active (IMPACT); Bettinger JA, Scheifele DW, et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009;28(3):220-4.
  8. Le Saux N, Bettinger JA, Wootton S, et al. Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection. Can J Infect Dis Med Microbiol 2009;20(4):e130-4.
  9. De Wals P, Nguyen VH, Erikson LJ, Guay M, Drapeau J, St-Laurent J. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004;22(9-10):1233-40.

Disclaimer: The recommendations in this position statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. Internet addresses are current at time of publication.